Myopathy associated with HMG-CoA reductase inhibitors (HMGRIs) and cyclosporin A: evaluation in a rat model.
Smith
P F
PF
Department of Safety Assessment, Merck Sharp & Dohme Research Laboratories, West Point, PA 19486.
Eydelloth
R S
RS
Grossman
S J
SJ
Stubbs
R J
RJ
Schwartz
M S
MS
Germershausen
J I
JI
MacDonald
J S
JS
D000818:Animals; D000924:Anticholesteremic Agents / Q000493:pharmacokinetics / Q000633:toxicity*; D016572:Cyclosporine / Q000493:pharmacokinetics / Q000633:toxicity*; D004357:Drug Synergism; D005260:Female; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008148:Lovastatin / Q000031:analogs & derivatives / Q000493:pharmacokinetics / Q000633:toxicity; D009132:Muscles / Q000187:drug effects / Q000473:pathology; D009135:Muscular Diseases / Q000097:blood / Q000139:chemically induced* / Q000473:pathology; D009336:Necrosis; D017035:Pravastatin / Q000493:pharmacokinetics / Q000633:toxicity; D051381:Rats; D011919:Rats, Inbred Strains; D019821:Simvastatin; D013329:Structure-Activity Relationship
D000924:Anticholesteremic Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D016572:Cyclosporine; C064146:L 647318; D008148:Lovastatin; D019821:Simvastatin; D017035:Pravastatin